Adagene

ADAG · NASDAQ

$2.50+$0.21 (+9.17%)TodayMarket closed ·
Prev close $2.29

About ADAG

Adagene, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of novel antibody-based cancer immunotherapies. The firm is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.

Employees
128
Headquarters
Suzhou, Jiangsu
Listed
Feb 9, 2021
Sector
Health Care
Industry
Biotechnology

Leadership

Adagene executives
NameTitleSince
Peter Luo—2011
Tam Man Kin—2019
Zha Jiping——
Shang Jin——
She Xiaohong——
Li Yan——
Fangyong Du——
Xu Jc——
Ami Knoefler——
Dana Hu - Lowe——
Zeng Wenlin——
Zheng Songmao——
Gu Chunfang——
Zhou Ling——
Alexander Goergen——
Liu Guizhong——
Zhao Qinghai——
Wang Yuren——
Lefei Sun——
Cheung Andy——
Yuwen Liu——
Li Min——

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Adagene suppliers and customers
CompanyRelationshipCorrelation
Exelixis EXELSupplier and customer-0.34

Similar companies

Companies in the same industry as Adagene

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.